Skip to main content

Kaleido Biosciences, Inc. (KLDO)

NASDAQ: KLDO · IEX Real-Time Price · USD
5.82
-0.01 (-0.17%)
After-hours:Sep 17, 2021 6:24 PM EDT
5.83
0.38 (6.97%)
At close: Sep 17, 4:00 PM
Market Cap248.23M
Revenue (ttm)1.23M
Net Income (ttm)-90.08M
Shares Out42.58M
EPS (ttm)-2.34
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume358,664
Open5.49
Previous Close5.45
Day's Range5.43 - 5.93
52-Week Range5.04 - 20.50
Beta-0.32
AnalystsBuy
Price Target18.00 (+208.7%)
Est. Earnings DateNov 2, 2021

About KLDO

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. It a...

IndustryPharmaceuticals
IPO DateFeb 28, 2019
Employees82
Stock ExchangeNASDAQ
Ticker SymbolKLDO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for KLDO stock is "Buy." The 12-month stock price forecast is 18.00, which is an increase of 208.75% from the latest price.

Price Target
$18.00
(208.75% upside)
Analyst Consensus: Buy

News

FDA Questions Kaleido Biosciences 'Non-IND' COVID-19 Trial

The FDA has issued a warning letter to Kaleido Biosciences Inc (NASDAQ: KLDO), blasting its “failure to submit Investigational New Drug applications for a clinical trial with an investigational new drug...

1 week ago - Benzinga

Kaleido Biosciences to Participate in the Morgan Stanley 19th Annual Virtual Global Healthcare Conference

LEXINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micro...

2 weeks ago - GlobeNewsWire

Kaleido Biosciences, Inc. (KLDO) Reports Q2 Loss, Lags Revenue Estimates

Kaleido Biosciences, Inc. (KLDO) delivered earnings and revenue surprises of 5.08% and -15.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Kaleido Biosciences Reports Second Quarter 2021 Financial Results

--On track to report topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis by end of third quarter-- --Kaleido and the COPD Foundation to collaborate on the de...

1 month ago - GlobeNewsWire

Kaleido Biosciences and the COPD Foundation Announce a Strategic Collaboration to Advance KB109 into Phase 2 Clinical...

On track to initiate Phase 2 trial in the first quarter of 2022 On track to initiate Phase 2 trial in the first quarter of 2022

1 month ago - GlobeNewsWire

Kaleido Biosciences Announces New Chairperson Appointment to its Board of Directors

Current Director Theo Melas-Kyriazi appointed Chairperson of the Board of Directors Current Director Theo Melas-Kyriazi appointed Chairperson of the Board of Directors

1 month ago - GlobeNewsWire

Kaleido Biosciences to Participate in the 41st Annual Canaccord Genuity Growth Conference

LEXINGTON, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...

1 month ago - GlobeNewsWire

Kaleido Biosciences, Inc. (KLDO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Kaleido Biosciences, Inc. (KLDO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Kaleido Biosciences to Participate in the JMP Securities Life Sciences Conference

LEXINGTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...

3 months ago - GlobeNewsWire

Kaleido Biosciences Reports First Quarter 2021 Financial Results

--Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109's potential to reduce healthcare utilization and recovery time; initiating IND application to support further development-...

4 months ago - GlobeNewsWire

Kaleido Biosciences Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic ...

LEXINGTON, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to tr...

4 months ago - GlobeNewsWire

Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit

LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbi...

5 months ago - GlobeNewsWire

Biotech company Kaleido develops oral therapy for COVID-19

Dan Menichella, Kaleido CEO, joins Yahoo Finance's Anjalee Khemlani, Alexis Christoforous and Kristin Myers to discuss the utilization of oral therapeutic KB109 for COVID-19 and emerging variants.

5 months ago - Yahoo Finance

Kaleido (KLDO) Reports Positive Results from COVID-19 Study

Kaleido (KLDO) announces impressive results from a study on KB109 in patients with mild-to-moderate COVID-19.

5 months ago - Zacks Investment Research

Kaleido Biosciences Stock Is Trading Higher On Positive KB109 Data In COVID-19 Study

Kaleido Biosciences Inc (NASDAQ: KLDO) reported positive results from a non-IND study of KB109 in patients with mild-to-moderate COVID-19. KB109 demonstrated an overall favorable safety and tolerability...

5 months ago - Benzinga

Kaleido Biosciences Reports Positive Results from Non-IND Study Demonstrating a Reduction in COVID-19 Related Healthc...

KB109 demonstrated favorable safety and tolerability profile

5 months ago - GlobeNewsWire

Kaleido Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results

Topline data from two ongoing COVID-19 studies with KB109 expected in Q1 2021

6 months ago - GlobeNewsWire

Kaleido Biosciences to Present at Chardan's 3rd Annual Microbiome Medicines Summit

LEXINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micro...

6 months ago - GlobeNewsWire

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at th...

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

6 months ago - PRNewsWire

Kaleido Biosciences (KLDO) Sees Hammer Chart Pattern: Time to Buy?

Kaleido Biosciences (KLDO) has been struggling lately, but the selling pressure may be coming to an end soon.

6 months ago - Zacks Investment Research

Kaleido Biosciences Announces the Exercise of the Underwriters' Option to Purchase Additional Shares of Common Stock

LEXINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...

7 months ago - GlobeNewsWire

Why Corcept Therapeutics, Acasti Pharma And More Are Moving Today

Corcept Therapeutics (NASDAQ: CORT) shares were trading lower Tuesday after the company reported preliminary fourth-quarter sales results and issued fiscal year 2021 sales guidance. Corcept Therapeutics...

Other symbols:ACSTCORTTMDX
7 months ago - Benzinga

Kaleido Biosciences Announces Pricing of Public Offering of Common Stock

LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...

7 months ago - GlobeNewsWire

Kaleido Biosciences Announces Proposed Public Offering of Common Stock

LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...

7 months ago - GlobeNewsWire

Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therap...

LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone Symp...

7 months ago - GlobeNewsWire